OptimizeRx Stock Is Believed To Be Significantly Overvalued

Author's Avatar
GF Value
Apr 20, 2021
Article's Main Image

The stock of OptimizeRx (NAS:OPRX, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $50.31 per share and the market cap of $845.5 million, OptimizeRx stock gives every indication of being significantly overvalued. GF Value for OptimizeRx is shown in the chart below.

OptimizeRx GF Value Chart

Because OptimizeRx is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which averaged 33.2% over the past three years and is estimated to grow 44.59% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. OptimizeRx has a cash-to-debt ratio of 23.42, which is better than 85% of the companies in the industry of Healthcare Providers & Services. The overall financial strength of OptimizeRx is 7 out of 10, which indicates that the financial strength of OptimizeRx is fair. This is the debt and cash of OptimizeRx over the past years:

debt and cash

It is less risky to invest in profitable companies, especially those with consistent profitability over long term. A company with high profit margins is usually a safer investment than those with low profit margins. OptimizeRx has been profitable 1 over the past 10 years. Over the past twelve months, the company had a revenue of $43.3 million and loss of $0.16 a share. Its operating margin is -4.93%, which ranks worse than 71% of the companies in the industry of Healthcare Providers & Services. Overall, the profitability of OptimizeRx is ranked 3 out of 10, which indicates poor profitability. This is the revenue and net income of OptimizeRx over the past years:

Revnue and Net Income

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term stock performance of a company. A faster growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of OptimizeRx is 33.2%, which ranks better than 91% of the companies in the industry of Healthcare Providers & Services. The 3-year average EBITDA growth rate is 72.1%, which ranks better than 97% of the companies in the industry of Healthcare Providers & Services.

Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, OptimizeRx's return on invested capital is -3.71, and its cost of capital is 6.69. The historical ROIC vs WACC comparison of OptimizeRx is shown below:

ROIC vs WACC

In conclusion, the stock of OptimizeRx (NAS:OPRX, 30-year Financials) appears to be significantly overvalued. The company's financial condition is fair and its profitability is poor. Its growth ranks better than 97% of the companies in the industry of Healthcare Providers & Services. To learn more about OptimizeRx stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

Rating:
0 / 5 (0 votes)
Author's Avatar